FRO – Q4 2022 Presentation
Please find enclosed the presentation of Frontline plc´s fourth quarter 2022 results to be held on the webcast /
Globe Newswire28-02-2023, 20:21
Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26
